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Abstract
The ubiquitin–proteasome system degrades ubiquitin-modified
proteins to maintain protein homeostasis and to control signalling.
Whole-genome sequencing of patients with severe deafness and
early-onset cataracts as part of a neurological, sensorial and cuta-
neous novel syndrome identified a unique deep intronic homozygous
variant in the PSMC3 gene, encoding the proteasome ATPase subunit
Rpt5, which lead to the transcription of a cryptic exon. The protea-
some content and activity in patient’s fibroblasts was however unaf-
fected. Nevertheless, patient’s cells exhibited impaired protein
homeostasis characterized by accumulation of ubiquitinated proteins
suggesting severe proteotoxic stress. Indeed, the TCF11/Nrf1 tran-
scriptional pathway allowing proteasome recovery after proteasome
inhibition is permanently activated in the patient’s fibroblasts. Upon
chemical proteasome inhibition, this pathway was however impaired
in patient’s cells, which were unable to compensate for proteotoxic
stress although a higher proteasome content and activity. Zebrafish
modelling for knockout in PSMC3 remarkably reproduced the human
phenotype with inner ear development anomalies as well as catar-
acts, suggesting that Rpt5 plays a major role in inner ear, lens and
central nervous system development.
Keywords cataract; deafness; neurosensory disease; proteasome; PSMC3
Subject Categories Genetics, Gene Therapy & Genetic Disease; Neuroscience
DOI 10.15252/emmm.201911861 | Received 5 December 2019 | Revised 4 May
2020 | Accepted 7 May 2020
EMBO Mol Med (2020) e11861
Introduction
Early-onset deafness is one of the most common causes of develop-
mental disorder in children (prevalence rate of 2–4/1,000 infants),
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and identically, early-onset cataract is the most important cause of
paediatric visual impairment worldwide (prevalence form 2–13.6/
10,000 according to regions) accounting for 10% of the causes of
childhood blindness. Each condition can be attributed to environ-
mental causes (intrauterine infections, inflammation, trauma or
metabolic diseases) or to genetic causes with a well-recognized very
high level of genetic heterogeneity with 59 known genes causing
early-onset cataracts and 196 genes known to cause severe deafness
(Azaiez et al, 2018; Reis & Semina, 2018). Patients presenting both
entities simultaneously, early-onset severe deafness and congenital
cataracts, are thought to be mainly due to teratogenic exposure
during pregnancy especially infections and are, nowadays, consid-
ered to be very rare. Indeed, only very few genetic inherited entities
associating both congenital cataracts and deafness have been
reported so far. The Aymé-Gripp syndrome (cataract, deafness,
intellectual disability, seizures and Down syndrome like facies) has
been recently linked to de novo pathogenic variants in the MAF
gene, a leucine zipper-containing transcription factor of the AP1
superfamily (Niceta et al, 2015). In addition, dominant pathogenic
variants in WFS1 (recessive loss-of-function variants are responsible
for Wolfram syndrome) have been described in children with
congenital cataracts and congenital deafness presenting in the
context of neonatal/infancy-onset diabetes (De Franco et al, 2017).
Herein, using whole-genome sequencing, we describe a novel
homozygous non-coding pathogenic variant in PSMC3 associated
with severe congenital deafness and early-onset cataracts and vari-
ous neurological features in three patients from a very large consan-
guineous family. PSMC3 encodes the 26S regulatory subunit 6A also
known as the 26S proteasome AAA-ATPase subunit (Rpt5) of the
19S proteasome complex responsible for recognition, unfolding and
translocation of substrates into the 20S proteolytic cavity of the
proteasome (Tanaka, 2009). The proteasome is a multiprotein
complex involved in the ATP-dependent degradation of ubiquiti-
nated proteins to maintain cellular protein homeostasis and to
control the abundance of many regulatory molecules. The 26S
proteasome consists of two complexes: a catalytic 28-subunit barrel
shaped core particle (20S) that is capped at the top or the bottom by
one 19 subunit regulatory particle (19S). The core particle contains
the catalytic subunits b1, b2 and b5 exhibiting caspase-, trypsin-
and chymotrypsin-like activities, respectively. Recognition of a
substrate with the requisite number and configuration of ubiquitin
is mediated principally by both Rpn10 and Rpn13 subunits, which
act as ubiquitin receptors (Deveraux et al, 1994; Husnjak et al,
2008). To allow substrate degradation, ubiquitin is first removed by
Rpn11, a metalloprotease subunit in the lid (Yao & Cohen, 2002).
The globular domains of a substrate are then unfolded mechanically
by a ring-like heterohexameric complex consisting of six distinct
subunits, Rpt1 to Rpt6, which belong to the ATPases associated with
diverse cellular activities (AAA) family (Chen et al, 2016). PSMC3
encodes for Rpt5 involved in the substrate unfolding and transloca-
tion, which are then presumably catalysed (Lam et al, 2002;
Tanaka, 2009).
In mammalian cells, a major compensation mechanism for
proteasome dysfunction is governed by the ER membrane-resident
TCF11/Nrf1 protein (Radhakrishnan et al, 2010; Steffen et al,
2010; Sotzny et al, 2016). Typical stimuli for TCF11/Nrf1 activa-
tion include proteasome inhibition and/or impairment, which
results in the release of C-terminal processed TCF11/Nrf1
fragment from the ER membrane following a complex series of
molecular events involving the enzymes NGLY1 and DDI2. The
cleaved TCF11/Nrf1 fragment enters then into the nucleus and
acts as a transcription factor to promote the expression of ARE-
responsive genes including 19S and 20S proteasome subunits,
thereby augmenting the pool of proteasomes so that protein
homeostasis can be preserved (Radhakrishnan et al, 2010; Steffen
et al, 2010; Sotzny et al, 2016).
We suggest that biallelic loss of PSMC3 causes a novel autosomal
recessive syndrome with varying degrees of neurosensorial dysfunc-
tions including the combination of cataract and deafness. Functional
analysis of patient’s cells revealed that although normal amount of
proteasome proteins can be observed in steady-state conditions, the
cells are unable to adapt to proteotoxic stress. The use of zebrafish
morpholinos and CRIPSR-Cas9 assays confirmed the same combina-
tion of sensory phenotypes upon inactivating PSMC3 expression.
Results
Patient phenotypes
Three patients with a novel syndromic neurosensory-cutaneous
presentation consulted independently to our clinical centre over a
period of 15 years. Careful analysis revealed that they originated
from the same small village (Amarat) in the Kayseri region of
Turkey and belong to the same large extended consanguineous
family (Fig 1A). The proband is a male individual (II.4) diagnosed
at the age of 8 months with profound perceptive deafness and
subsequently benefited from a cochlear implantation. He was
referred at the age of 2 years old to our centre because of visual
impairment due to bilateral cataracts for which he underwent bilat-
eral lensectomies. With years, he developed severe developmental
delay and severe intellectual deficiency (no words, limited compre-
hension). Several facial features were noted (Table 1 and Fig 1B).
In addition, severe autistic features were revealed at the age of
2.5 years old (Table 1). A full metabolic exploration was normal. At
the age of 5, he developed subcutaneous deposits at the level of the
knees and elbows (Fig 1C). At the age of 10, he developed white
hair at the level of the two legs as opposed to the dark pigmented
hair on the rest of the body. More recent examination revealed also
a peripheral polyneuropathy of lower limbs. The two other patients
(II.2 and II.7) were referred at the age of 1 year old and share the
same severe perceptive deafness (for which they also benefited from
a cochlear implantation), visual impairment due to bilateral obstru-
ent cataracts (for which they also had bilateral lensectomies) and
subcutaneous deposits. Patient II.2 did not present with autistic
features but had moderate developmental delay (able to read and
write few words, but no understanding of complex sentences) and a
significative polyneuropathy of the lower limbs (more pronounced
that II.4). Patient II.7 did not present with polyneuropathy as
opposed to the other patient, but like patient II.4, he presented
severe developmental delay with autistic features. For each patient,
otoacoustic emissions were positive at birth. However, deafness
was suspected for all of them within the early months of life, respec-
tively, 8 months (II.4) and 1 year and 3 months (II.2, II.7). Auditory
brainstem response was in favour of profound deafness (no
response at 110 dB). The MRI did not reveal any anomalies of the
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cochleovestibular nerves or labyrinthitis. However, the temporal
bone CT scan analysis of patient II.7 revealed lateral semicircular
canal malformations with the absence of the bony island in the right
ear and a small bony island in the left ear (Fig 1D).
Identification of a rare deep intronic variation in PSMC3
During the years of follow-up, each patient was explored for known
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Figure 1. Family pedigree and cDNA analysis.
A Family pedigree. Variant segregation analysis of PSMC3. Electropherogram of a part of intron 10 of PSMC3 encompassing the identified variation (c.[1127 + 337A>G];
[1127 + 337A > G], p.[(Ser376Arg15*)];[(Ser376Arg15*)]) in the affected individuals, their unaffected parents and siblings. The variation was found at the homozygous
state in the affected individuals (II.2, II.4, II.7) and at the heterozygous state in the parents (I.1, I.2, I.3, I.4, I.5, I.6) and was either at the heterozygous state (II.5) or
absent in the unaffected siblings (II.1, II.3, II.6).
B Face (up) and profile (down) photographs for patients II.4 (a: 8 yo, b: 16 yo), II.2 (c: 6 yo, d: 14 yo) and II.7 (e: 1 yo, f: 7 yo) over time. One can observe prominent
supraciliary arches, synophrys, sunken cheeks, short philtrum and retrusion in the malar region.
C Subcutaneous calcifications found only on knees (g: 9 yo and h: 16 yo) and on elbows (i: 9 yo) of patient II.4. White hair were present only on the legs of the 3
patients as illustrated for patient II.4 (j: 16 yo).
D Temporal bone CT scan from patient II.7 (left column) and a control (right column) showing malformation of the semicircular canal. The left ear is shown on the
upper panels while the right ear on the lower panels.
E Amplification of the cDNA fragment between exons 9–10 and 11 of PSMC3 showing the abnormally spliced RNA fragment. One band at 180 bp representing the
normal allele is seen for the control and two bands for the individual II.4 (pathologic allele at 300 bp).
F Schematic representation for the incorporation of the 114 bp intronic sequence resulting from the c.1127 + 337A > G deep intronic variation on the mRNA. Sanger
sequencing of the fragment between exons 9–10 and 11 of the PSMC3 cDNA obtained from patient II.4 fibroblasts’ RNA, showing the insertion of the 114 bp cryptic
exon. As a comparison, the schematic representation and sequence from a control individual are shown above.
Source data are available online for this figure.
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GJB2, one of the patient being an heterozygous carrier of the
c.30delG well-known recurrent pathogenic variant) but also using
larger assays such as whole-exome sequencing (WES) with a
specific focus on known deafness and cataract genes (Appen
dix Table S1) and standard chromosomal explorations (karyotype
and chromosomal microarray analysis), but all were negative (see
Appendix Supplementary Methods). Considering that affected indi-
viduals may harbour pathogenic variants in a region not covered by
the WES (i.e. intronic and intergenic) or not well detected (i.e. struc-
tural variations) (Geoffroy et al, 2018b), we applied whole-genome
sequencing (WGS) to the three affected individuals (II.2, II.4 and
II.7) and two healthy individuals (II.1 and II.3). Given the known
consanguinity in the family, our analysis was focused on homozy-
gous variations and more specifically within homozygous regions
defined by the SNP arrays (Appendix Fig S1). In addition to the clas-
sical filtering strategy including functional criteria, frequency in
population-based databases and cosegregation analysis (see Materi-
als and Methods), we defined a list of 4,846 potentially interacting
genes with the already known human cataract (59) and deafness
genes (196) (Appendix Fig S2). This strategy allowed us to identify
from the ~5,000,000 variations per WGS, six variations out of which
a unique homozygous variant in the intron 10 of the PSMC3 gene
(c.1127 + 337A>G, p. (?)) remained of interest (Appendix Table S2
and Fig S3). This variant was not present in any variation database
(e.g. gnomAD) and is predicted to create a new donor splice site.
Interestingly, among others PSMC3 was shown to interact
(Appendix Tables S3 and S4, and Fig S4) with CHMP4B (MIM
610897), ACTG1 (MIM 102560) and GJB6 (MIM 604418) involved in
cataract and deafness.
Effect of the variation on PSMC3 expression and localization
In order to assess the effect of this deep intronic variation, we inves-
tigated the expression of the gene in the patient’s fibroblasts. The
suspected new donor site could be associated with multiple acceptor
sites within intron 10 (Appendix Fig S5). RNA analysis revealed an
additional band specific to the affected patient that was further
explored by Sanger sequencing (Fig 1E). The consequence of this
variation is the inclusion of a cryptic 114 bp exon during the splic-
ing process based on the intronic sequence (r.1127_1127+1insACTC-
CACCCCTCATCTGAAGGCACAGAGGCTGGAGGCACTTAGTTTCCT
GGCCTCACACCTCAGCCCATTAACACACGCCAGGAATGGCCGGGAC
CAGATGGACTTGAGTTCAG) (Fig 1F) that is predicted to add 15aa
(LeuHisProSerSerGluGlyThrGluAlaGlyGlyThr) at position 376
followed by a stop (p.(Ser376Argfs15*)). Analysis at the RNA level
showed a significantly reduced level of PSMC3 mRNA as well as the
presence of an additional truncated form (Appendix Fig S6).
However, no difference in expression or localization of the PSMC3
protein could be detected between the control and the patient cells
under normal condition, indicating that the truncated form is proba-
bly not stable (Appendix Fig S7).
Functional effect of the PSMC3 variant to the proteasome
function and assembly
Given the role of PSMC3 in protein degradation, we determined the
intracellular level of ubiquitinated proteins in patient cells compared
to controls. Our results show an increased level of ubiquitinated
proteins in patient cells (Fig 2A and B), suggesting that the protea-
somal proteolysis is less efficient. Having shown a possible effect on
proteasome function, we next investigated how the variant could
affect the proteasome assembly and dynamics. First, in standard
condition, PSMC3 protein and its partners were immunoprecipitated
from either controls’ or patient’s fibroblasts and revealed by mass
spectrometry (Fig 2C). The PSMC3 protein was detected in the input
control and patient, indicating that the variant does not affect the
protein stability of the remaining wild-type allele confirming the
Western blot analysis. Looking at the interacting partners, one can
notice that each proteasome subunit could be detected revealing no
apparent defect in the general organization of the proteasome.
However, protein abundance of each proteasome subcomplex esti-
mated from the number of mass spectrometry spectra observed
between the controls and the patient (Appendix Table S5) shows a
general increase of the proteasome subunits (approximately 20%).
Looking more specifically at each subcomplex, the increase is
mainly due to the core particle including the alpha and beta sub-
units with 1.5-fold for all PSMA proteins and most PSMB protein
and even a 2.0-fold increase for PSMB2/4/6, while PSMC and PSMD
remain at the same ratio.
To further characterize the consequences of the PSMC3 variant
on the functionality of the ubiquitin–proteasome system (UPS), cell
lysates derived from control and patient primary fibroblasts were
analysed by non-denaturing PAGE with proteasome bands being
visualized by their ability to hydrolyse the Suc-LLVY fluorogenic
peptide. As shown in Fig 3A, gel overlay assay for peptidase activity
revealed two strongly stained bands corresponding to the positions
of the 20S and 26S proteasome complexes, respectively. However,
no discernible differences could be detected in the chymotrypsin-
like activity of both 20S and 26S complexes between control and
patient cells, suggesting that peptide hydrolysis in the 20S prote-
olytic core is not substantially impaired by the PSMC3 pathogenic
variant. The notion that proteasome activity does not vary between
these two samples was further confirmed by monitoring the degra-
dation rate of the Suc-LLVY peptide directly in whole-cell extracts
from control and patient fibroblasts over a 180-min period that was
almost identical in both samples (Fig 3B). In order to characterize
the proteasome populations in cells carrying the deep intronic
PSMC3 homozygous variant, samples separated by non-denaturing
PAGE were subsequently analysed by Western blotting. As
expected, using an antibody against the proteasome subunit a6, two
major bands were observed in the 20S and 26S regions (Fig 3C).
Interestingly, the signal intensity for both proteasome complexes
was significantly stronger in patient fibroblasts, suggesting that the
amount of intracellular proteasome pools in these cells was higher
than those of control fibroblasts. Western blotting against the
PSMC3 subunit revealed two bands in the 26S proteasome area and
corresponding to single and double-capped proteasomes (19S-20S
and 19S-20S-19S, respectively) and confirmed the higher amount of
these complexes in patient cells (Fig 3C); however, there are some
lower bands corresponding to 19S precursor intermediates, indicat-
ing that assembly of 19S complexes is affected. As shown in Fig 3C,
staining for PA28-a, a subunit of the alternative proteasome regula-
tor PA28, revealed one major band corresponding to the position of
the 20S proteasome, indicating the 20S proteasomes in these
samples mainly consist of PA28-20S complexes. Again, patient
fibroblasts exhibited a stronger expression level of such homo-PA28
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complexes than their wild-type counterparts. To validate the notion
that the homozygous pathogenic variant results in increased assem-
bly of newly synthetized proteasome complexes, patient fibroblasts
were compared to control ones for their content in various protea-
some subunits using SDS–PAGE followed by Western blotting. As
illustrated in Fig 3D, the steady-state expression level of most of the
b, a and Rpt subunits was substantially higher in the patient’s cells.
A minor band corresponding to the expected size of the truncated
RPT5 variant (i.e. 43,548.95 Da) was observed in the patient’s
sample (Fig 3D, long exposure time). Unexpectedly, the increased
proteasome content was accompanied by a parallel rise of ubiquitin-
modified proteins in these cells, suggesting that proteasomes from
patients bearing the homozygous PSMC3 pathogenic variant,
although being in greater number, are ineffective. Altogether, these
results point to a defective proteasome function in subjects carrying
the deep intronic homozygous PSMC3 pathogenic variant, which
seems to be compensated by an ongoing assembly of newly synthe-
tized 20S and 26S complexes.
We next sought to determine the impact of this variant on the
ability of the cells to respond to perturbed protein homeostasis
following proteasome dysfunction. To this end, both control and
patient cells were subjected to a 16-h treatment with the b5/b5i-
specific inhibitor carfilzomib in a non-toxic concentration prior to
SDS–PAGE and Western blotting analysis using various antibodies
specific for proteasome subunits. As shown in Fig 4, PSMC3 mutant
cells were endowed with higher amounts of immunoproteasome
subunits and proteasome activator PA28-a in untreated conditions
when compared to their wild-type counterparts. Most importantly,
control cells exposed to carfilzomib could successfully compensate
the applied proteotoxic stress by increasing their pools of intracellu-
lar proteasomes, as evidenced by elevated expression of all investi-
gated b- and Rpt subunits. As expected, this process was preceded
by the processing of the ER membrane-resident protein TCF11/Nrf1
(Fig 4), which is the transcription factor acting on nuclear genes
encoding 19S and 20S proteasome subunits (Radhakrishnan et al,
2010; Steffen et al, 2010; Sotzny et al, 2016). Strikingly, the level of
processed TCF11/Nrf1 in response to carfilzomib was much lower
in cells carrying the homozygous PSMC3 pathogenic variant than
that observed in control cells. Accordingly, the patient’s fibroblasts
were unable to upregulate their proteasome subunits following
proteasome inhibition, as determined by decreased expression levels
of proteasome subunits and PA28-a (Fig 4).
To confirm that the cellular phenotype of patient fibroblasts was
due to the homozygous PSMC3 variant, we next conducted rescue
experiments in which these cells were subjected to 24-h transfection
with an expression vector encoding wild-type PSMC3. As shown in
Fig 5A, patient cells overexpressing intact PSMC3 exhibited a dimin-
ished accumulation of K48-linked ubiquitin–protein conjugates when
compared to control cells or empty-vector cells, as determined by
Western blotting. Densitometry analysis of the ubiquitin band inten-
sities reveals that the pool of ubiquitin-modified proteins was signifi-
cantly reduced by about 20% in PSMC3-rescued patient fibroblasts at
24-h post-transfection (Fig 5B). In addition, introducing wild-type
PSMC3 into patient cells resulted in a decreased activation of TCF11/
Nrf1, as evidenced by the absence of the TCF11/Nrf1 processed form
under normal conditions (Fig 5C). Most importantly, overexpression
of wild-type PSMC3 successfully prevented the loss of proteasome
subunits and PA28-a in patient fibroblasts following carfilzomib
treatment (Fig 5C). Altogether, these data clearly identified the
homozygous PSMC3 mutant as the genetic cause of proteasome fail-
ure affecting protein homeostasis under stress conditions.
Effect of PSMC3 loss of function in zebrafish similar to
patients’ phenotype
To establish a functional link between the observed decreased
proteasome activity and the phenotype observed in the patients, we
next assessed the lens and the ear in the zebrafish model. The
zebrafish orthologue (Ensembl, ENSDARG00000007141) of human
PSMC3 is located on chromosome 7 with two predicted protein-
coding splice variants (404 and 427 amino acids). Both zebrafish
psmc3 isoforms share 83% sequence identity with the human ortho-
logue. We confirmed by in situ hybridization that psmc3 is mater-
nally expressed and not spatially restricted (Appendix Fig S8; Data
ref: Thisse & Thisse, 2004). Injection of morpholinos against psmc3
generated zebrafish morphants embryos that were examined at
4 days post-fertilization (dpf) for lens or ear abnormalities. The lens
size of morphants was slightly smaller than in control or uninjected
embryos (Appendix Fig S9A). For cataract detection, we used a
protocol based on confocal reflection microscopy, a labelling-free
non-invasive imaging method that enables the detection of abnor-
mal light reflection in the lens of living embryos (Fig 6A; Takamiya
Table 1. Clinical description of the patients with PSMC3 pathogenic
variants.
II.4 II.2 II.7
Birth date 24/12/2003 02/02/2005 15/03/2012
Neurosensorial features
Congenital cataract + + +
Strabismus +  +
Congenital deafness + + +
Facial dysmorphism features
Round ears +  
Synophrys +  
Short philtrum + + 
Malar region retrusion + + +
Prominent supraciliary arches + + +
Sunken cheeks + + +
Preauricular fibrochondroma   +
Thin upper lip + + 
Neurologic features
Developmental delay S M S











M, moderate; S, severe.
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Figure 2. Effect of the deep intronic PSMC3 variant on the proteasome function.
A Anti-ubiquitin Western blot in control and patient fibroblasts and total amount of proteins loaded (stainfree) showing increased ubiquitination in patient cells
(lane 4).
B Histogram showing the quantification of ubiquitin with Western blot assays. The data shown correspond to the sum of all bands detected by the anti-ubiquitin
antibody expressed as a percentage of the amount of ubiquitin in “Control 1” cells. Bars show mean of ten independent experiments  SD (n = 10, t-test *P < 0.01,
**P < 0.05).
C Mass spectrometry results from the co-immunoprecipitation with PSMC3 are displayed as the normalized total number of spectra count of each protein computed as
the mean from 3 controls (x axis) vs. the mean of patient II.4 triplicate. Proteasome subcomplexes are coloured according to the displayed legend, and standard ratio
lines are drawn.
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et al, 2016). Morpholino injections revealed significant abnormal
lens reflections in 95% of the morphants (n = 55), whereas only
2% of 5 bp mismatched morpholino-injected controls (n = 45) and
none of the uninjected embryos (n = 20) showed cataract (Fig 6B
and B0). The observed cataract was not due to increased apoptosis,
as TUNEL staining did not reveal more positive nuclei in the
morphant compared to wild-type embryos (Appendix Fig S10).
As deafness has been reported for all three human patients, we
subsequently examined the inner ear development of 4 dpf zebra-
fish morphants (Fig 6C). psmc3 morphants displayed a smaller ear
compared to control or uninjected embryos (Appendix Fig S9C).
Interestingly, the majority of morphants presented anomalies during
the semicircular canal morphogenesis. While the epithelium projec-
tions of all uninjected (n = 20) and all control-injected (n = 45)
embryos were fused and formed pillars after 4 dpf, the canal projec-
tions of morphants failed to fuse in 79% of the cases (n = 58,
Fig 6D and D0). The specificity of the morpholino was confirmed by
a rescue experiment by co-injecting the full-length splice morpho-
lino-resistant zebrafish psmc3 mRNA. The cataract phenotype was
rescued in ~ 58% of the cases (n = 60), while the ear phenotype
A C D
B
Figure 3. Fibroblasts derived from patient carrying the c.1127 + 337A>G homozygous PSMC3 variation exhibit an increased amount of both proteasome
complexes and ubiquitin–protein conjugates.
A Whole-cell lysates from control and patient (case index, CI) fibroblasts were assessed by 3–12% native-PAGE gradient gels with proteasome bands (30S, 26S and 20S
complexes) visualized by their ability to cleave the Suc-LLVY-AMC fluorogenic peptide.
B Ten micrograms of control and patient cell lysates was tested for their chymotrypsin-like activity by incubating them with 0.1 mM of the Suc-LLVY-AMC substrate at
37°C over a 180-h period of time in quadruplicates on a 96-well plate. Indicated on the y-axis are the raw fluorescence values measured by a microplate reader and
reflecting the AMC cleavage from the peptide. Bars show the mean of 4 independent experiments  SD.
C Proteasome complexes from control and patient fibroblasts separated by native-PAGE were subjected to Western blotting using antibodies specific for a6, Rpt5
(PSMC3) and PA28-a, as indicated.
D Proteins extracted from control and CI PSMC3 were separated by 10 or 12.5% SDS–PAGE prior to Western blotting using primary antibodies directed against ubiquitin
and several proteasome subunits and/or components including a6, b1, b; b5, b5i, Rpt2 (PSMC1), Rpt5 (PSMC3), Rpt3 (PSMC4), Rpt4 (PSMC6) and PA28-a, as indicated.
For the PSMC3 staining, two exposure times are shown. Arrow indicates an additional PSMC3 species corresponding to the expected size of the truncated PSMC3
variant. Equal protein loading between samples was ensured by probing the membrane with an anti-a-Tubulin antibody.
Source data are available online for this figure.
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was rescued in 76% of the cases (n = 60; Fig 6B0 and D0). The
outgrowth of the epithelial projections of the developing anterior
and posterior semicircular canals begins around 48 hpf. From 57 to
68 hpf, the projections fuse in the centre of the ear and form the
pillars. This is followed by the outgrowth of the projection of the
lateral semicircular canal around 57 hpf and completed by the
fusion with the other two pillars in the centre around 70 hpf (Geng
et al, 2013). To analyse the semicircular canal morphogenesis in
psmc3 morphants, life imaging was performed between 56 and
72 hpf in the transgenic line gSAIzGFF539A expressing a GFP signal
in all three pillars. In all morphants (n = 9), the projections failed to
fuse and form pillars during the observed time frame. In two
morphants (22%), the outgrowth of epithelial projections even
failed completely. In contrast, the projections of uninjected (n = 2)
and control-injected (n = 2) embryos fused during the observed
period in the centre of the ear and formed canal pillars (Movie
EV1). Previous studies showed that a reduced number or a smaller
size of otoliths, crystal-like structures required for the transmission
of mechanical stimuli to the hair cells, can lead to deafness and
balancing difficulties in zebrafish (Han et al, 2011; Stooke-Vaughan
et al, 2015). psmc3 morphants did not present any otolith defect
(Appendix Fig S11A–C). In addition, expression of otopetrin, a gene
required for proper otolith formation, was unaffected at 28 hpf and
4 dpf (Appendix Fig S9D).
As autism has been reported for one of the patients and brain
malformation has been reported previously in some autistic
patients and autistic zebrafish morphants (Elsen et al, 2009), we
investigated possible morphological brain changes in psmc3
morphants. In situ hybridization targeting brain markers such as
krox20, msxc, her8a and sox19b was performed on 24 hpf embryos
but did not reveal any obvious differences in their expression
patterns (Appendix Fig S12).
To confirm these results, we additionally used the CRISPR/Cas9
system to knockdown psmc3 (Fig 6B–D). The high cutting effi-
ciency of the CRISPR/Cas9 founders (F0) was evaluated to 55.2%
(gRNA1) and 53.7% (gRNA2) (Appendix Fig S13) (Etard et al,
2017). CRISPR/Cas9 founders (i.e. crispants) are often genetically
mosaics. However, in cases of highly efficient gRNAs, they have
been shown to recapitulate mutant phenotypes successfully (Küry
et al, 2017; Teboul et al, 2017; Paone et al, 2018). Both psmc3 cris-
pants used in this study displayed a cataract phenotype (100% of
gRNA1 + Cas9 (n = 20) and 95% of gRNA2 + Cas9 (n = 20),
whereas none of the control embryos (injected with gRNA1
(n = 20) or gRNA2 (n = 10) without the Cas9 protein) showed
abnormal lens reflections (Fig 6B and B0, and Appendix S13A and
A0). Moreover, we recapitulated the ear phenotype seen in psmc3
morphants. While the ear pillars of uninjected (n = 10) and
control-injected (n = 20) embryos formed after 4 dpf, the projec-
tions of both crispants failed to fuse in 65% of gRNA1 (n = 10)-
and 93% of gRNA2 (n = 30)-injected embryos (Fig 6D and D0, and
Appendix S13B and B0). Co-injection of gRNA2, Cas9 and the
psmc3 mRNA also led to a partial rescue of the lens and ear
phenotype with only 63% of abnormal lens reflection instead of
100% (n = 19) and 37% of unfused canal projections instead of
93% (n = 30; Fig 6D0). Performing an in situ hybridization examin-
ing the mRNA expression of versican a and versican b, two genes
suggested to be required for a proper canal fusion event (Geng
et al, 2013), significant differences could be observed after 72 hpf.
Indeed, both genes were highly expressed in the whole ear tissue,
whereas versican a was not expressed and versican b was
restricted to the dorsolateral septum in wild-type or control-
injected embryos (Appendix Fig S14B–D).
Figure 4. Patient fibroblasts carrying the c.1127 + 337A>G homozygous
PSMC3 variation exhibit an exhausted TCF11/Nrf1 processing pathway,
which prevents them to upregulate proteasome subunits in response to
proteotoxic stress.
Control and patient (index case, IC PSMC3) fibroblasts were exposed to a 16-h
treatment with 30 nM of the proteasome inhibitor carfilzomib or left untreated
(as a negative control). Following treatment, cells were collected and subjected
to RIPA-mediated protein extraction prior to SDS–PAGE and subsequent
Western blotting using antibodies specific for ubiquitin, TCF11/Nrf1, Rpt1
(PSMC2), Rpt3 (PSMC4), Rpt5 (PSMC3), Rpt6 (PSMC5), b1, b2, b5, b5i, b1i, PA28-a
and a-Tubulin (loading control) as indicated. For the TCF11/Nrf1 staining, two
exposure times are shown.
Source data are available online for this figure.
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The inner ear possesses hair cells to sense both vestibular and
auditory stimuli. These apical structures consist of a bundle of
villi-like structures called stereocilia and kinocilia, collectively
referred to as a hair bundle. Because these cilia have been shown
to play a key role at least in mechanosensation during develop-
ment (Kindt et al, 2012), we immunostained crispants (sgRNA2
A C
B
Figure 5. Overexpression of wild-type PSMC3 in patient fibroblast restores intracellular protein homeostasis and prevents the loss of proteasome subunit
expression in response to proteasome inhibition.
A Control and/or patient (index case, IC PSMC3) fibroblasts were subjected to a 24-h transfection with pcDNA3.1/empty vector (mock) or pcDNA3.1/PSMC3 prior to
RIPA-mediated protein extraction and subsequent Western blotting using antibodies specific for ubiquitin, PSMC3 (i.e. Rpt5) and a-Tubulin (loading control).
B Densitometry analysis showing the relative ubiquitin contents detected by Western blotting in patient fibroblasts exposed to either pcDNA3.1/empty vector (mock) or
pcDNA3.1/PSMC3, as indicated. The y-axis represents the per cent changes in densitometry measurements (of pixel intensities using ImageJ), which are set as 100%
for cells transfected with the pcDNA3.1/empty vector (mock) at 24 post-transfection (n = 4, *P < 0.05, t-test). Bars show the mean  SEM.
C Patient (index case, IC PSMC3) fibroblasts transfected with either pcDNA3.1/empty vector (mock) or pcDNA3.1/PSMC3 were exposed to a 30-nM treatment of
carfilzomib or left untreated (as a negative control). After 16 h, cells were collected and subjected to RIPA-mediated protein extraction prior to SDS–PAGE and
subsequent Western blotting using antibodies specific for ubiquitin, TCF11/Nrf1, Rpt1 (PSMC2), Rpt3 (PSMC4), Rpt5 (PSMC3), Rpt6 (PSMC5), b1, b2, b5, b5i, PA28-a and
a-Tubulin (loading control), as indicated. For the TCF11/Nrf1 staining, two exposure times are shown.
Source data are available online for this figure.
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injected with Cas9) and control-injected embryos (sgRNA2 without
Cas9) at 5 dpf using anti-acetylated tubulin antibody. In 40% of
crispants (n = 15), a reduced number of cilia was observed while
their number in control-injected embryos (n = 10) was similar to
that of uninjected embryos (n = 10) (Fig 6E+E0). In order to exam-








Figure 6. psmc3 morphants and F0 mosaic zebrafish exhibit cataract and show abnormalities during the semicircular canal development in the ear.
A Scheme of a zebrafish eye.
B, B0 Cataract detection revealed abnormal lens reflection in psmc3 morpholino (MO)-mediated knockdown but not in controls (uninj, ctrl-mo). Similarly, abnormal lens
reflection was also observed in embryos injected with sgRNA + Cas9 but not in sgRNA-injected embryos without Cas9 (sgRNA2). Co-injection of wt psmc3 mRNA
with either psmc3-mo or sgRNA2 + Cas9 reduced the number of embryos presenting abnormal lens reflection. Scale bar = 50 lm. (B0) Quantification of embryos
with abnormal lens reflection.
C Representative image of a zebrafish ear at 4 dpf. kc = kinocilia.
D, D0 Brightfield images of inner ear development (lateral position). (D) Epithelial projections were fused and formed canal pillars in 4-day-old uninjected and control-
injected fish (ctrl-mo, sgRNA2) but not in morphants (mo) and crispants (sgRNA2 + Cas9). Co-injection of wt psmc3 mRNA with psmc3-mo or sgRNA + Cas9
reduced the number of embryos presenting abnormal ear phenotype. Black asterisks indicate fused pillars. Red arrowheads mark unfused projections. Scale
bar = 100 lm. (D0) Quantification of embryos with abnormal projection outgrowth.
E, E0 An anti-acetylated tubulin antibody (green) staining revealed an abnormal amount of kinocilia in psmc3 crispants (sgRNA2 + Cas9) compared to uninjected and
control-injected embryos (sgRNA2). Nuclei are stained in blue with DAPI. Representative images show kinocilia of the lateral cristae. Scale bar = 20 lm. (E0)
Quantification of embryos with an abnormal amount of kinocilia.
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did not reveal any obvious difference between wild-type and
morphant embryos. However, we observed that the length of the
cilia was decreased when compared to wild-type embryos
(Appendix Fig S15).
Taken together, these zebrafish assays confirm that psmc3 plays
a very important role in the development of a transparent lens and
the semicircular canals of the inner ear—reminiscent of the human
phenotype described herein.
Discussion
In this study, we describe a novel homozygous deep intronic splice
variant, identified in three patients with an unusual neurosensorial
disease combining early-onset deafness, cataracts and subcutaneous
deposits, in PSMC3 encoding one of the proteasome subunit. Clinical
data and functional analysis in patient’s cells and zebrafish proved
the effect of the variation and the consequences leading to a reces-
sive form of proteasome deficit with a haploinsufficiency mecha-
nism. The observation of a neurosensory disease broadens the
spectrum of ubiquitin–proteasome system (UPS)-related disorders.
Sequencing the entire genome of patients gives access to the whole
spectrum of their variations and possibly disease-causing ones.
WGS is a powerful tool (Belkadi et al, 2015) helping to identify vari-
ations not covered or missed by WES such as structural variations
(Geoffroy et al, 2018b) or deep intronic variations (Vaz-Drago et al,
2017). Interestingly, in this study, we combined to WGS, homozy-
gosity mapping and in silico predicted interactors to narrow down to
the region of PSMC3. The three patients carried an homozygous
deep intronic variation (i.e. > 100 bases from the exon–intron
boundaries) (Vaz-Drago et al, 2017) with a predicted splicing effect
on the PSMC3 gene that we confirmed on the patient’s cells. We
then focused on demonstrating the effect of this variation at the
level of the proteasome.
To our knowledge, this is the first report of a human biallelic
pathogenic variant occurring in one of the ATPase Rpt subunits of
the base of the 19S regulatory particle. Recently, de novo pathogenic
variations in the non-ATPase subunit PSMD12 (Rpn5) of the 19S
regulator lid of the 26S complex have been reported in six patients
with neurodevelopmental disorders including mainly intellectual
disability (ID), congenital malformations, ophthalmic anomalies (no
cataracts), feeding difficulties, deafness (unspecified type for two
patients/6) and subtle facial features (Küry et al, 2017). PSMD12
variants have been also associated with a large family with ID and
autism and one simplex case with periventricular nodular hetero-
topia (Khalil et al, 2018). PSMD12 is highly intolerant to loss-of-
function (LoF) variations, and the most likely effect is haploinsuffi-
ciency due to the de novo heterozygote occurrence of loss-of-func-
tion truncating, non-sense or deletion variants. Interestingly,
according to the gnomAD and DDD data (Huang et al, 2010;
preprint: Karczewski et al, 2019), PSMC3 is also predicted to be
extremely intolerant to LoF variation. Indeed, the haploinsufficiency
score of PSMC3 is 4.76 that is within the high ranked genes (e.g. HI
ranges from 0 to 10%) from the DECIPHER data. The pLI score
(0.96) makes it among the highest intolerant genes (e.g. a score
> 0.9 defines the highest range) with only three observed LoF vari-
ants vs. 23.2 predicted and confidence interval = 0.13). This
explains also maybe the rarity of LoF variations found to date in this
gene. In our cases, this is the first time that biallelic class five varia-
tions are reported in one of the proteasome subunit delineating a
recessive mode of inheritance. Nevertheless, the fact that the
homozygous variation is affecting the splicing machinery and leads
to a reduced but not abolished expression of PSMC3 could mimic a
possible haploinsufficiency mechanism although we cannot rule out
a semi-dominant effect of the truncated Rpt5 form. It should also be
noted that the acquisition of neurodevelopmental phenotypes upon
proteasome dysfunction is not necessarily restricted to LoF varia-
tions in genes of the 19S regulatory particle, since recent work
demonstrated that biallelic variants in the PSMB1 subunit of the 20S
core particle were associated with intellectual disability and devel-
opmental delay (Ansar et al, 2020).
Both proteomic and biochemical approaches undertaken in this
study revealed that the deep intronic homozygous PSMC3 variation
is associated with increased amounts of 26S and 20S-PA28 protea-
some complexes (Figs 2C and 3). The observation that patient cells
concomitantly increase their intracellular pool of ubiquitin–protein
conjugates (Figs 2A and 3D) is surprising and strongly suggests that
such proteasomes are defective. In support of this notion, we found
that, although carrying greater amounts of proteasomes, patient
fibroblasts did not exhibit higher chymotrypsin-like activity
compared to control cells, which can be at least partly explained by
upregulation of PA28 and the concomitant increased peptide hydrol-
ysis (Ma et al, 1992; Fig 3A and B). The C-terminus of Rpt5, which
is supposed to be truncated in the patient due to the deep intronic
splice variant, has been shown to be important for gate opening of
the a-ring of the 20S proteasome core complex and for assembly of
the 19S complex (Smith et al, 2007; Singh et al, 2014). Thus, an
expression of this truncated Rpt5 variant even in low mounts may
disturb proteasome assembly and function. These data led us to
conclude that the increased steady-state expression level of the
proteasome subunits observed in patient fibroblasts might reflect a
constitutive de novo synthesis of proteasomes, which aims to
compensate the dysfunctional ones. Strikingly and in contrast to
control cells, TCF11/Nrf1 is constitutively processed in patient cells
(Fig 4), confirming that patients’ proteasomes were impaired. This,
in turn, gives rise to a pathological vicious circle of events in which
TCF11/Nrf1 and defective proteasomes stimulate each other (Fig 7).
We reasoned that such a process may result in a pathway overload,
which in turn reduces the ability of TCF11/Nrf1 to respond to
further proteotoxic stress. Consistent with this hypothesis and
unlike control cells, patient fibroblasts were not capable of upregu-
lating their proteasome subunits when challenged with proteasome
inhibitor carfilzomib (Fig 4). Importantly, overexpression of wild-
type PSMC3 could successfully rescue the phenotype of these cells
by (i) restoring ubiquitin homeostasis (Fig 5A and B), (ii) sparing
the TCF11/Nrf1 pathway (Fig 5C) and (iii) preserving proteasome
subunit expression following carfilzomib treatment (Fig 5C). This
result is of great importance, as it confirms that the deep intronic
homozygous PSMC3 variation in patient cells is responsible for their
inability to cope with proteotoxic stress. Because cataract and semi-
circular canal malformations are observed in zebrafish embryos
depleted with PSMC3, and a fortiori proteasomes, these data estab-
lished a clear cause and effect relationship between the deep
intronic PSMC3 variant and the acquisition of patients’ phenotype.
On the other hand, one cannot exclude that the pathogenesis of the
homozygous PSMC3 variation may involve additional mechanisms.
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Because target genes of TCF11/Nrf1 include anti-inflammatory
factors (Widenmaier et al, 2017; Yang et al, 2018), it is also conceiv-
able that inflammation might play a role in this process. This
assumption would be in line with the observation that subjects suf-
fering from other loss-of-function proteasome variations such as
PSMB8 (Agarwal et al, 2010; Arima et al, 2011; Liu et al, 2012),
PSMA3, PSMB4, PSMB9 (Brehm et al, 2015) and/or POMP (Poli
et al, 2018) exhibit an inflammatory phenotype including joint
contractures. This notion is further reinforced by the fact that
patient fibroblasts constitutively express type I and/or II interferon
(IFN) genes such as those encoding the immunoproteasome subu-
nits b5i, b1i as well as PA28-a (Fig 4). In any case, the potential
contribution of innate immunity to the pathogenesis of the homozy-
gous PSMC3 variant via TCF11/Nrf1 warrants further investigation
(Sotzny et al, 2016; Poli et al, 2018).
The ubiquitin–proteasome system (UPS) is a protein degradation
pathway that regulates the intracellular level of proteins involved in
a very wide variety of eukaryote cellular functions. Thus, it is not
surprising that this pathway is related to multiple human conditions
including cataract, where an overburden of dysfunctional and aggre-
gated proteins cannot be adequately removed by the UPS (Shang &
Taylor, 2012). Moreover, protein degradation dysfunction is recog-
nized as a widespread cause of neurodegenerative diseases such as
Parkinson, Huntington or Alzheimer diseases. Several inherited rare
disorders have been shown to be related to directly UPS dysfunction
in enzymes of the ubiquitin conjugation machinery: UBE3A in
Angelman syndrome (Kishino et al, 1997, p. 3), UBE2A in X-linked
syndromic ID (Nascimento et al, 2006), UBE3B in Kaufman oculo-
cerebrofacial syndrome (classified as blepharophimosis—mental
retardation syndrome) or other related enzymes such as HUWE1 an
ubiquitin ligase in X-linked for dominant ID syndrome (Froyen et al,
2008; Moortgat et al, 2018) and OTUD6B a deubiquitinating enzyme
for neurodevelopmental disability with seizures and dysmorphic
features (Santiago-Sim et al, 2017). The phenotypic tropism for
Figure 7. Schematic diagram depicting TCF11/Nrf1 processing pathway in response to proteasome dysfunction and/or proteotoxic stress in patient carrying
the deep intronic homozygous PSMC3 variation (left) and in healthy subjects (right).
Under normal conditions, TCF11/Nrf1 is a short-lived ER membrane (endoplasmic reticulum)-resident protein, which is rapidly subjected to proteasome-mediated
degradation following retro-translocation to the cytosol by ER-associated degradationmachinery (ERAD). In case of proteasome dysfunction (i.e. proteotoxic stress), the half-
life of TCF11/Nrf1 is prolonged and become then a substrate for the NGLY1 and DDI2, thereby giving rise to a C-terminal cleaved fragment that enters into the nucleus. After
nuclear translocation, cleaved TCF11/Nrf1 associates with Maf and promotes the expression of proteasomes genes, so that protein homeostasis can be restored. In patients
carrying the c.1127 + 337A>G homozygous PSMC3 variation, defective proteasomes promote a constitutive activation of TCF11/Nrf1, thereby resulting in increased assembly
of newly synthetized non-functional proteasomes, which in turn activate TCF11/Nrf1 again. Over-activation of TCF11/Nrf1 results in pathway exhaustion thus rendering
patient cells incapable of responding to further proteotoxic stress.
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neurodevelopmental disorders especially with intellectual disability
and other brain dysfunctions (autism, seizures, brain malforma-
tions) seems to be overall a hallmark of the gene alterations related
to the UPS inherited dysfunctions. In the family presented herein,
all three patients had various neurodevelopmental anomalies
(autism, ataxia, mild ID) and mild facial dysmorphism.
However, the striking clinical presentation of the cases reported
herein is the combination of early-onset deafness and early-onset
cataracts that motivated (independently) the referral of the three
cases. These features have not yet been related to this group of
disorders to date. Moreover, this association has only been reported
twice in larger syndromic forms such as the dominant form of WFS1
but in the context of neonatal/infancy-onset diabetes (De Franco
et al, 2017) and the Aymé-Gripp syndrome (including also intellec-
tual disability, seizures and Down syndrome like facies) with de
novo pathogenic variants in the MAF gene (Niceta et al, 2015). Vari-
ations in the later one were shown to impair in vitro MAF phospho-
rylation, ubiquitination and proteasomal degradation.
The zebrafish model was extremely useful to demonstrate the
effect of a reduced psmc3 expression leading to inner ear anomalies
and lens opacities. The overall development of the lens and inner
ear as well as the underlying gene regulatory networks are highly
conserved throughout evolution (Cvekl & Zhang, 2017). Pathogenic
variations or knockdown of genes implicated in human cataract
and/or deafness in zebrafish has been shown to recapitulate similar
phenotypes (Busch-Nentwich, 2004; Takamiya et al, 2016; Gao
et al, 2017; Mishra et al, 2018; Yousaf et al, 2018). Using two
strategies (morpholino and CRISPR/Cas9), the fish developed a
cataract and ear phenotype that could be rescued. We did not
observe other obvious anomalies. Interestingly, a reduction of
proteasome activity has previously been associated with lens
defects in zebrafish. The knockout of the zebrafish gene psmd6 and
the knock down of psmd6 and psmc2, both encoding for proteins of
the proteasome, resulted in a severe impairment of lens fibre devel-
opment. Cataract was also proposed as a consequence of disrupted
lens fibre differentiation (Richardson et al, 2017). The ear pheno-
type of the psmd6 mutant and both psmd6 morphants was not
assessed (Imai et al, 2010). A direct link between the UPS and audi-
tory hair cell death or impaired semicircular canal morphogenesis
has not been described in zebrafish yet. However, knockdown of
atoh1, a gene regulated by the UPS, has been shown to severely
affect hair cell development in the inner ear of zebrafish (Millimaki
et al, 2007). The malformation of canal pillars observed in zebrafish
psmc3 morphants and crispants might be also a secondary effect, as
abnormal sensory cristae with few hair cells have been previously
assumed to lead to an abnormal development of semicircular canals
(Haddon & Lewis, 1991; Cruz et al, 2009). Patients’ hearing loss
seems rapidly progressive—in the earlier months of life—rather
than congenital: OAE were present at birth but had disappeared
upon deafness diagnostic. Cochlear implant was possible in all
three patients and the results are correlated with the patients’
condition (autistic features) and time of implantation. Indeed,
patients II.4 and II.7 show severe autistic features and were
implanted late (i.e. after the age of 2 and more than a year after
deafness diagnostic). They did not develop language and do not use
their cochlear implant, and audiometric assessment is impossible.
Patient II.2 was implanted at the age of 22 months (i.e. 7 months
after deafness diagnostic), and his tone audiometry results are
excellent. Despite wearing his implant every day for 10 years, he
still shows severe language delay.
In conclusion, our work demonstrates the implication of a deep
intronic variant in a novel ultra-rare neurosensorial syndrome with
early-onset cataract and deafness in one of the proteasome subunit,
PSMC3. Although de novo dominant variations have been associated
with several proteasome-related disorders, we report for the first
time a biallelic pathogenic variant. Our observations strongly
suggest that the amount of PSMC3 is critically implied in the devel-
opment and maintenance of the inner ear and the lens.
Materials and Methods
Patients and ethics
The three cases have consulted independently and were enrolled
subsequently by the CARGO (reference centre for rare eye diseases
at the Strasbourg University Hospital, France). All participants were
assessed by a clinical geneticist, a neuropaediatrician, an Ear-Nose-
Throat specialist, a dermatologist and a paediatric ophthalmologist.
Written consent for research and publication (including photogra-
phy) was obtained for all study participants. This research followed
the tenets of the Declaration of Helsinki. Approval was obtained
from our institutional review board “Comité Protection des Person-
nes” (EST IV, N◦DC-20142222). The identified gene was submitted
to the GeneMatcher tool, but no other patient with the same pheno-
type could be identified (Sobreira et al, 2015).
Homozygosity regions
Three affected individuals (II.2, II.4 and II.7) and two unaffected
individuals (II.1 and II.3) were analysed with the Affymetrix
GeneChip Mapping 250K Array Xba 240 (Affymetrix, Santa Clara,
CA). Sample processing and labelling were performed according to
the manufacturer’s instructions. Arrays were hybridized on a Gene-
Chip Hybridization Oven 640, washed with the GeneChip Fluidics
Station 450 and scanned with a GeneChip Scanner 3000. Data were
processed by the GeneChip DNA Analysis Software version 3.0.2
(GDAS) to generate SNP allele calls. An average call rate > 99% was
obtained. Homozygosity regions were identified as regions of
homozygosity longer than 25 adjacent SNPs. Shared regions of
homozygosity are visualized by the HomoSNP software (IGBMC,
Strasbourg), which displays one patient per line (Appendix Fig S1).
Three regions of homozygosity of, respectively, 0.3, 2.1 and 1.3 Mb
on chromosome 11 (11:44,396,024–44,668,374; 11:45,574,574–
47,684,908; 11:66,066,993–67,349,899) are shared between the
affected and not the healthy individuals.
Whole-exome sequencing
Whole-exome sequencing (WES) was performed in 2014 for the
three affected siblings (II.2, II.4, II.7) and one healthy brother (II.6)
by the IGBMC (Institut de Génétique et de Biologie Moléculaire et
Cellulaire, Illkirch-Graffenstaden, France) Microarray and Sequenc-
ing platform. Exons of DNA samples were captured using the in-
solution enrichment methodology (Agilent SureSelect All Exon XT2
50 Mb Kit) and sequenced with an Illumina HiSeq 2500 instrument
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to generate 100 bp paired-end reads. The reads were mapped to the
reference human genome (GRCh37/hg19) using the Burrows-
Wheeler Aligner (BWA v0.7.1) (Li & Durbin, 2009). The Haplo-
typeCaller module of the Genome Analysis ToolKit (GATK v3.4-46)
was used for calling both SNV and indel (DePristo et al, 2011).
Structural variations (SV) were called using CANOES (Backenroth
et al, 2014).
From 96,222 to 102,072 genetic variants (SNV/indel/SV) were
identified per individual from the WES analysis (Appendix
Table S1). Bioinformatics analyses (see Materials and Methods)
highlighted a unique homozygous missense variation in the DGKZ
gene (NM_001105540.1:c.1834G>A, p.Ala612Thr) encoding for the
Diacylglycerol Kinase Zeta, located in a homozygous region of inter-
est on chromosome 11 (Appendix Table S1). This variant, reported
previously with a gnomAD frequency of 0.018%, was predicted
tolerated by SIFT (Ng & Henikoff, 2003) and neutral by PolyPhen-2
(Adzhubei et al, 2010) and was finally manually ruled out, as we
were unable to explain the patients phenotype based on the gene
function.
Whole-genome sequencing
Whole-genome sequencing was performed in 2016 for the three
affected siblings (II.2, II.4, II.7) and two healthy brothers (II.1, II.6)
by the Centre National de Recherche sur le Génome Humain
(CNRGH, Evry France). Genomic DNA was used to prepare a library
for WGS using the Illumina TruSeq DNA PCR-Free Library Prepara-
tion Kit. After normalization and quality control, qualified libraries
were sequenced on a HiSeq2000 platform (Illumina Inc., CA, USA),
as paired-end 100 bp reads. At least three lanes of HiSeq2000 flow
cell were produced for each sample, in order to reach an average
sequencing depth of 30×. Sequence quality parameters were
assessed throughout the sequencing run, and standard bioinformat-
ics analysis of sequencing data was based on the Illumina pipeline
to generate FASTQ files for each sample. The sequence reads were
aligned to the reference sequence of the human genome (GRCh37)
using the Burrows-Wheeler Aligner (BWA V7.12) (Li & Durbin,
2009). The UnifiedGenotyper and HaplotypeCaller modules of the
Genome Analysis ToolKit (GATK) (DePristo et al, 2011), Platypus
(https://github.com/andyrimmer/Platypus) and Samtools (Li et al,
2009) were used for calling both SNV and indel. Structural Varia-
tions (SV) were called using SoftSV (Bartenhagen & Dugas, 2016).
Moreover, each known cataract and deafness genes were visually
inspected with IGV (Thorvaldsdóttir et al, 2013).
Bioinformatics analysis
Annotation and ranking of SNVs/indels and structural variations
were performed, respectively, by VaRank (Geoffroy et al, 2015) (in
combination with Alamut Batch, Interactive Biosoftware, Rouen,
France) and by AnnotSV (Geoffroy et al, 2018a). Variant effect on
the nearest splice site was predicted using MaxEntScan (Yeo &
Burge, 2004), NNSplice (Reese et al, 1997) and Splice Site Finder
(Shapiro & Senapathy, 1987). Very stringent filtering criteria were
applied to filter out non-pathogenic variants: (i) variants repre-
sented with an allele frequency of more than 1% in public variation
databases including the 1000 Genomes (1000 Genomes Project
Consortium et al, 2015), the gnomAD database (Lek et al, 2016),
the DGV (MacDonald et al, 2014) or our internal exome database,
and (ii) variants in 50 and 30 UTR, downstream, upstream, intronic
and synonymous locations without pathogenic prediction of local
splice effect. The PSMC3 nomenclature is based on the accession
number NM_002804.4 from the RefSeq database (O’Leary et al,
2016). Genomic coordinates are defined according to GRCh37/hg19
assembly downloaded from the University of California Santa Cruz
(UCSC) genome browser (Tyner et al, 2017).
Sanger confirmation and segregation
The variant confirmation and the cosegregation analysis with the
phenotype in the family member were performed by Sanger
sequencing after PCR amplification of 50 ng of genomic DNA
template. The primers were designed with Primer 3 (http://frodo.
wi.mit.edu/primer3) and are detailed in Appendix Table S6. Bidirec-
tional sequencing of the purified PCR products was performed by
GATC Sequencing Facilities (Konstanz, Germany).
Plasmid construction
The DNA sequence for PSMC3 encoding the full-length Rpt5 protea-
some subunit (NM_002804.4) was amplified by PCR from a pcDNA/
Zeo (+) expression vector encoding a N-terminally HA-tagged Rpt5
(kind gift from Dr. Richard Golnik, Charité Universitätsmedizin
Berlin) and cloned into pcDNA3.1/myc-HIS version B (Invitrogen)
to construct an untagged PSMC3/Rpt5 using the EcoRV and XhoI
restriction sites. The resulting pcDNA3.1/PSMC3 construct was
sequenced (Microsynth Seqlab, Göttingen) before being used for
transfection experiments.
RNA and protein analysis using the patient’s cells
Fibroblasts of patient II.4 and control individuals were obtained by
skin biopsy as previously described (Scheidecker et al, 2015). Three
sex and age matched controls were used.
RNA was extracted from skin fibroblasts of individual II.4 and a
healthy unrelated control using RNeasy RNA kit (Qiagen); then, we
performed reverse transcription using the iScriptTM cDNA Synthesis
Kit (Bio-Rad, Hercules, CA).
Protein analysis includes Western blot for which extracted
proteins using the RIPA Buffer (89901 Thermo Scientific) comple-
mented with protease inhibitor cocktail (Roche 06538282001) from
primary fibroblasts of affected and control individuals were loaded
onto Mini-PROTEAN TGX gels (Bio-Rad).
Immunofluorescence assays were performed using primary
fibroblasts from patient and control individuals grown in Nunc
Lab-Tek chamber slides (Thermo Scientific, Waltham, MA, USA)
fixed with 4% paraformaldehyde, incubated with PBS 0.5% Triton
X-100 for 10 min and blocked with PBS-20% FCS. Cells were then
incubated for 1 h with primary antibodies, washed three times in
PBS, incubated for 1 h with secondary antibody and DAPI, washed
again in PBS and mounted in Elvanol No-Fade mounting medium
before observation on a fluorescence microscope (Zeiss Axio
Observer D1) at a ×400 magnification. The primary antibodies
were directed against the N- and C-terminal part of PSMC3. The
secondary antibody was goat anti-mouse Alexa Fluor coupled 568
IgG (Invitrogen).
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Accumulation of ubiquitinated proteins has been observed using
a dedicated Western blot. Skin fibroblasts from three controls and
the affected individual were recovered in ice-cold RIPA buffer with
protease inhibitors (“Complete EDTA-free”; Roche Diagnostics, 1
tablet in 10 ml buffer) and 25 mM N-ethylmaleimide (NEM, diluted
freshly in ethanol to prevent artefactual deubiquitination), left on
ice for 45 min, centrifuged for 10 min at 13,360 g, supernatant
recovered and 5× Laemmli buffer added. Bands were quantified
relative to the total amount of protein loaded (stainfree) using Image
Lab. All bands corresponding to the various ubiquitinated proteins
were added and expressed relative to the amount of ubiquitinated
proteins in control 1 fibroblasts. The mean of six independent exper-
iments was calculated and represented as a histogram, and a
Student’s t-test was performed to determine the significance.
Primary and secondary antibodies used in these experiments study
as well as their dilution are described in Appendix Table S7.
Co-immunoprecipitation and mass spectrometry analysis
PSMC3 protein and its partners were immunoprecipitated from
patient’s fibroblasts using magnetic microparticles (MACS purifica-
tion system, Miltenyi Biotec) according to the manufacturer’s
instructions and as previously described (Stoetzel et al, 2016, 15).
Briefly, PSMC3 complexes were captured with an anti-PSMC3 anti-
body (Abcam ab171969) and the target and its associated proteins
were purified on the protein G microbeads (Miltenyi Biotec).
Proteins were eluted out of the magnetic stand with 1× Laemmli
buffer (Bio-Rad). To optimize reproducibility, co-immunoprecipita-
tion experiments were carried out in affinity triplicates on exactly
1.1 mg of proteins for each sample. For negative controls, halves of
each sample were pooled and immunoprecipitated with the protein
G beads, omitting the antibody.
Protein extracts were prepared as described in a previous study
(Waltz et al, 2019). Each sample was precipitated with 0.1 M
ammonium acetate in 100% methanol, and proteins were resus-
pended in 50 mM ammonium bicarbonate. After a reduction–alkyla-
tion step (dithiothreitol 5 mM–iodoacetamide 10 mM), proteins
were digested overnight with sequencing-grade porcine trypsin
(1:25, w/w, Promega, Fitchburg, MA, USA). The resulting vacuum-
dried peptides were resuspended in water containing 0.1% (v/v)
formic acid (solvent A). One fifth of the peptide mixtures were anal-
ysed by nanoLC-MS/MS an Easy-nanoLC-1000 system coupled to a
Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific, USA)
operating in positive mode. Five microlitres of each sample was
loaded on a C-18 precolumn (75 lm ID × 20 mm nanoViper, 3 lm
Acclaim PepMap; Thermo) coupled with the analytical C18 analyti-
cal column (75 lm ID × 25 cm nanoViper, 3 lm Acclaim PepMap;
Thermo). Peptides were eluted with a 160-min gradient of 0.1%
formic acid in acetonitrile at 300 nl/min. The Q-Exactive Plus was
operated in data-dependent acquisition mode (DDA) with Xcalibur
software (Thermo Fisher Scientific). Survey MS scans were acquired
at a resolution of 70K at 200 m/z (mass range 350–1,250), with a
maximum injection time of 20 ms and an automatic gain control
(AGC) set to 3e6. Up to 10 of the most intense multiply charged ions
(≥ 2) were selected for fragmentation with a maximum injection
time of 100 ms, an AGC set at 1e5 and a resolution of 17.5K. A
dynamic exclusion time of 20 s was applied during the peak selec-
tion process.
MS data were searched against the Swiss-Prot database (release
2019_05) with Human taxonomy. We used the Mascot algorithm
(version 2.5, Matrix Science) to perform the database search with a
decoy strategy and search parameters as follows: carbamidomethy-
lation of cysteine, N-terminal protein acetylation and oxidation of
methionine were set as variable modifications; tryptic specificity
with up to three missed cleavages was used. The mass tolerances in
MS and MS/MS were set to 10 ppm and 0.05 Da, respectively, and
the instrument configuration was specified as “ESI-Trap”. The
resulting “.dat” Mascot files were then imported into Proline v1.4
package (http://proline.profiproteomics.fr/) for post-processing.
Proteins were validated with Mascot pretty rank equal to 1, 1% FDR
on both peptide spectrum matches (PSM) and protein sets (based on
score). The total number of MS/MS fragmentation spectra was used
to quantify each protein in the different samples.
For the statistical analysis of the co-immunoprecipitation data,
we compared the data collected from multiple experiments against
the negative control IPs using a homebrewed R package as
described previously (Chicois et al, 2018) except that that the size
factor used to scale samples was calculated according to the DESeq
normalization method [i.e. median of ratios method (Anders &
Huber, 2010)]. The package calculates the fold change and an
adjusted P-value corrected by Benjamini–Hochberg for each identi-
fied protein (and visualizes the data in volcano plots).
Native-PAGE and proteasome in-Gel peptidase activity assay
Patient and control fibroblasts were lysed in equal amounts of TSDG
buffer (10 mM Tris pH 7.0, 10 mM NaCl, 25 mM KCl, 1.1 mM
MgCl2, 0.1 mM EDTA, 2 mM DTT, 2 mM ATP, 1 mM NaN3, 20%
Glycerol) prior to protein quantification using a standard BCA assay
(Pierce) following the manufacturer’s instructions. Twenty micro-
grams of whole-cell extracts were loaded on 3–12% gradient native-
PAGE gels (Invitrogen) and subsequently subjected to a 16-h elec-
trophoresis at 45 V using a running buffer consisting of 50 mM
BisTris/Tricine, pH 6.8. Chymotrypsin-like activity of the separated
proteasome complexes was then measured by incubating 0.1 mM of
the suc-LLVY-AMC substrate (Bachem) at 37°C for 20 min in a final
volume of 10 ml of overlay buffer (20 mM Tris, 5 mM MgCl2, pH
7.0). Proteasome bands were then visualized by exposure of the gel
to UV light at 360 nm and detected at 460 nm using an Imager.
Measurement of proteasome activity in crude extracts
Ten micrograms of whole-cell extracts deriving from control and
patient fibroblasts was tested for chymotrypsin-like activity by expos-
ing the cell lysates to 0.1 mM of the Suc-LLVY-AMC peptide. Assays
were carried out in a 100 ll reaction volume of ATP/DTT lysis buffer
at 37°C. The rate of cleavage of fluorogenic peptide substrate was
determined by monitoring the fluorescence of released aminomethyl-
coumarin using a plate reader at an excitation wavelength of 360 nm
and emission wavelength of 460 nm over a period of 120 min.
Western blot analysis
For Western blotting, equal amounts of RIPA (50 mM Tris pH 7.5,
150 mM NaCl, 2 mM EDTA, 1 mM N-ethylmaleimide, 10 lM MG-
132, 1% NP-40, 0.1% SDS) buffered protein extracts from control
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and patient fibroblasts were separated in SDS-Laemmli gels (12.5 or
10%). Briefly, following separation, proteins were transferred to
PVDF membranes (200 V for 1 h) blocked with 1× Roti-Block (Carl
Roth) for 20 min at room temperature under shaking and subse-
quently probed overnight at 4°C with relevant primary antibodies.
The anti-Alpha6 (clone MCP20), anti-Beta1 (clone MCP421), anti-
Beta2 (clone MCP165), anti-Rpt1 (PSMC2, BML-PW8315), anti-Rpt2
(PSMC1, BML-PW0530), anti-Rpt3 (PSMC4, clone TBP7-27), anti-
Rpt4 (PSMC6, clone p42-23), anti-Rpt5 (PSMC3, BML-PW8310) and
anti-Rpt6 (PSMC5, clone p45-110) primary antibodies were
purchased from Enzo Life Sciences. The anti-Beta1i (LMP2, K221)
and anti-PA28-a (K232/1) are laboratory stocks and were used in
previous studies(Poli et al, 2018). Antibodies specific for Beta5
(ab3330) and a-tubulin (clone DM1A, ab7291) were purchased from
Abcam. Primary antibodies specific for TCF11/Nrf1 (clone D5B10)
and ubiquitin (clone D9D5) were obtained from Cell Signaling Tech-
nology. The anti-Beta5i antibody (LMP7, clone A12) was a purchase
from Santa Cruz Biotechnology Inc. After incubation with the
primary antibodies, membranes were washed three times with PBS/
0.4% Tween and incubated with anti-mouse or anti-rabbit HRP
conjugated secondary antibodies (1/5,000). Visualization of
immunoreactive proteins was performed with enhanced chemilumi-
nescence detection kit (ECL) (Bio-Rad). The ImageJ 1.48v software
was used for densitometry analysis of the ECL signals.
Zebrafish analysis
Zebrafish (Danio rerio) maintenance and husbandry
In this study, the zebrafish wild-type line AB2O2 (University of
Oregon, Eugene) and the transgenic line gSAIzGFF539A (National
Institute of Genetics, Mishima, Japan) were used and maintained at
28°C under a 14-h light and 10-h dark cycle as described previously
(Westerfield, 2000). When fish reached sexual maturity, zebrafish
couples were transferred to breeding tanks the day before and
crossed after the beginning of the next light cycle. Fertilized zebra-
fish eggs were raised at 28.5°C in 1× Instant Ocean salt solution
(Aquarium Systems, Inc.). Zebrafish husbandry and experimental
procedures were performed in accordance with German animal
protection regulations (Regierungspräsidium, Karlsruhe, Germany,
AZ35-9185.81/G-137/10). In all experiments, samples (n) represent
a random selection of a bigger cohort. The status of the zebrafish
was always known to the experimenters.
Microinjections
Injections were performed as described before (Müller et al, 1999).
Morpholinos psmc3-mo (TGTGAATCACAGTATGAAGCGTGCC, Gene-
tools LLC, Oregon) and ctrl-mo (5-bp mismatched) (TGTCAATGA-
GAGTATCAACCGTGCC, Genetools LLC, Oregon) were injected at
0.2 mM (Appendix Fig S16). CRISPR guide RNAs were designed with
ChopChop software (Labun et al, 2019) and synthesized with the
MEGAshortscript T7 Transcription Kit (Ambion) according to the
manufacturer’s instructions. For CRISPR/Cas9 injections, 300 ng/ll
of Cas9 protein (GeneArt Platinum Cas9 Nuclease, Invitrogen) and
300 ng/ll guide RNA were combined. Guide RNA1 (G1 binding
sequence: AGATCCTAATGACCAAGAGGAGG) targets exon 4, and
Guide RNA2 (G2 binding sequence: CAGGATATCCACCCTGTTAGT
GG) targets exon 9. The Web interface PCR-F-Seq q (http://iai-gec-se
rver.iai.kit.edu) was used to quantify the cutting efficiency of both
guide RNAs (Etard et al, 2017). For the life imaging experiment, the
transgenic line gSAIzGFF539A, marking the semicircular canals, was
generated using the Gal4-UAS system as described previously
(Asakawa et al, 2008). For rescue experiments, mRNA of zebrafish
psmc3 was synthesized using the mMESSAGE mMACHINE system
(Ambion). Zebrafish psmc3 mRNA was injected at a final concentra-
tion of 10 ng/ll.
PCR amplification and cloning
Total RNA from 24 to 72 hpf zebrafish embryos was extracted using
Tri-reagent (Invitrogen, Carlsbad, CA) and reverse transcribed using
M-MLV Reverse Transcriptase (Promega, Germany). To analyse the
expression pattern of psmc3 in zebrafish embryos, we amplified and
cloned a 956 bp psmc3 fragment into the pGEMT-easy vector
(Promega). For the synthesis of DIG-labelled RNA probes, we used
Apa1 to linearize the plasmid and SP6 to transcribe the anti-sense
RNA DIG probes. To exclude possible off-target effects caused by
morpholino or CRISPR/Cas9 injection, a rescue experiment was
performed. Full-length psmc3 was cloned into pCS2+ using EcoRI,
linearized with NotI and psmc3 full-length RNA synthesized using
the mMESSAGE mMACHINE SP6 Kit (Ambion). To verify the effi-
ciency of morpholino (psmc3-mo), we extracted total RNA from
morpholino-injected embryos using Tri-reagent (Invitrogen, Carls-
bad, CA), transcribed mRNA into cDNA using M-MLV Reverse Tran-
scriptase (Promega, Germany) and checked the effect on the psmc3
splice sites by RT–PCR using the amplification conditions as
described before (Appendix Fig S16B; Müller et al, 1999). Using
Sanger Sequencing, the CRISPR/Cas9 efficiency was assessed
(Appendix Fig S16C and D).
Whole-mount in situ hybridization
In situ hybridization was performed as previously described (Crow
& Stockdale, 1986; Oxtoby & Jowett, 1993; Costa et al, 2002). To
suppress melanogenesis, 20 hpf zebrafish embryos were transferred
and raised in water supplemented with 200 mM 1-phenyl 2-thiourea
(PTU). Probes targeting the messenger RNAs of the genes krox20,
msxc, her8a and sox19b were obtained from Armant et al (2013).
Plasmids to generate probes targeting otopetrin, versican and versi-
can b were provided by the laboratory of Tanya Whitfield.
Immunohistochemistry
Immunostaining of whole zebrafish embryos after 5 dpf was
performed as previously described (Leventea et al, 2016) and imaged
with Leica TCS SP5 confocal microscope. Antibodies are indicated in
Appendix Table S7. For TUNEL staining, we used the ApopTag Red
In Situ Apoptosis Detection Kit (Millipore). For imaging the hair cells,
we incubated 5 dpf embryos in a solution of 6 lM of FM1-43 (Life
technology), for 1 min, wash them in E3 water, anaesthetized with
0.0168% (w/v) MESAB and embedded them into 0.5% (w/v) low
melting point agarose chilled to 37°C in a lateral position.
Microscopy
To examine the eye and ear phenotype in morphants and crispants,
we anaesthetized living embryos with 0.0168% (w/v) MESAB (tri-
caine methanesulfonate, MS-222; Sigma-Aldrich, Taufkirchen,
Germany) and embedded them into 0.5% (w/v) low melting point
agarose chilled to 37°C in a lateral position with one eye/ear facing
towards the objective. Confocal reflection microscopy was used to
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examine zebrafish eyes for abnormal light reflection evoked through
cataract as previously described (Takamiya et al, 2016) and imaged
with the Leica TCS SP2 confocal system with a 63× water immersion
objective. Brightfield and fluorescence real-time imaging of zebra-
fish ears were acquired using the Leica TCS SP5 confocal micro-
scope with a 63× and 40× water immersion objective.
Statistics
For in vitro and in vivo experiments, sample sizes were chosen
according to the standard practice in the field. For humans, sample
size was limited by the patient’s sample available. In all zebrafish
experiments, samples (n) represent a random selection of a bigger
cohort. The status of the zebrafish was always known to the experi-
menters. Results are reported as mean  standard deviation (SD) or
(SEM) for the number of experiments indicated in the legends of each
figure or table. Statistical analyses were performed using either Excel
(Microsoft, USA) or the Prism software (GraphPad, USA). In most of
the cases, we used a Student’s t-test to compare two groups of
normally distributed data. Significance levels and number of samples/
replicates are indicated in each figure legends. All P-values for main
Figures and appendix figures can be found in the Appendix Table S8.
Data availability
The data sets produced in this study are available in the following
databases:
• WGS sequences: European Genome-Phenome Archive (EGA)
EGAS00001003942 (https://ega-archive.org/studies/EGAS000010
03942)
• Protein interaction AP-MS data: Protein identifications database
(PRIDE) PXD015836 (http://www.ebi.ac.uk/pride/archive/projec
ts/PXD015836)
• Human variations: ClinVar SCV000864220.1 (https://www.ncbi.
nlm.nih.gov/clinvar/SCV000864220)
Expanded View for this article is available online.
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The paper explained
Problem
Early-onset deafness is one of the most common causes of develop-
mental disorder in children (prevalence of 2–4/1,000 infants), and
similarly, early-onset cataract is the most important cause of paedi-
atric visual impairment worldwide (prevalence 2–13.6/10,000)
accounting for 10% of the causes of childhood blindness. Many genes
have already been implicated for each of these conditions indepen-
dently but only very few genes identified when cataract and early-
onset deafness occur together. Indeed, patients with both conditions
are very rare and often linked to teratogenic exposure during preg-
nancy. In this study, we therefore aim at identifying the molecular
cause of cases with syndromic early-onset deafness and congenital
cataracts.
Results
Using whole-genome sequencing combined with homozygosity
mapping and bioinformatics prioritization, we uncovered a homozy-
gous deep intronic variation in the PSMC3 gene in three affected
patients from a very large consanguineous family presenting with
early-onset cataract and deafness. PSMC3 encodes one of the
proteasome subunits and more specifically Rpt5, the 26S proteasome
AAA-ATPase subunit of the 19S proteasome complex responsible for
recognition, unfolding and translocation of substrates into the 20S
proteolytic cavity of the proteasome. The ubiquitin–proteasome
system (UPS) is a major cellular system that degrades ubiquitin-
modified proteins to maintain protein homeostasis and to control
signalling including development. Using multiple approaches includ-
ing proteomics, cellular biology (on patient’s cells) and animal
modelling (zebrafish), we could confirm the impact of this variation
(transcription of a cryptic exon introducing a stop codon) on protea-
some function and linked this to the patients’ phenotype.
Impact
This is the first implication of the 26S proteasome AAA-ATPase
subunit in a disease with the description of biallelic pathogenic
variations in the context of the emerging proteasomopathies that
include PSMA3, PSMB1, PSMB4, PSMB8, PSMB9, PSMD12, PSMG2 and
POMP genes that are linked to loss-of-function variations. These
results open new insights into the role of the proteasome or at
least PSMC3 in inner ear, lens and central nervous system develop-
ment. Identifying novel genes implicated in such rare diseases will
improve the genetic counselling and give affected families the
opportunity to have access to preimplantation genetic diagnosis
and prenatal testing.
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